

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

II. REMARKS**A. Status of the Claims**

Claims 1, 3-4, 6, 8-20, 24-33, and 35-39 are currently pending in the present application. Claims 2, 7, and 34 have been cancelled without prejudice. Claims 1, 6, 8-9, 12, 15, 18, 24, 25, 27, 28 and 36 have been amended without prejudice. New claims 37-39 have been added. Support for the amendments to claims 1, 6, 8, 9, 12, 15, 18, 24 and 27 and new claims 37-39 can be found, throughout the specification (e.g., in Table 1 of the Examples, and in the Figures). It is respectfully submitted that no new matter has been added by virtue of the present amendment.

B. Timmins reference

Applicants acknowledge with appreciation the Examiner's removal of the Timmins reference (U.S. Patent No. 6,475,521) as prior art in view of the Declaration accompanying the October 6, 2003 response.

C. Rejection under 35 U.S.C. § 112

Applicants acknowledge with appreciation the Examiner's removal of the previous rejection of claims 1-4 and 30 under 35 U.S.C. § 112, second paragraph in view of the previous amendment to claim 1.

Claim 36 is rejected under 35 U.S.C. § 112, second paragraph, on the grounds of indefiniteness. The Examiner states that "[c]laim 36 recites the limitation 'the evening meal' in line 2," and that "[t]here is insufficient antecedent basis for this limitation in the claim."

In response, claim 36 has been amended without prejudice to recite “an evening meal.” (emphasis added). Therefore, the Examiner is respectfully requested to remove this rejection.

D. Claim Objections

Claims 2, 7, and 34 were objected to under 37 CFR 1.75(c), “as being of improper dependent form to further limit the subject matter of a previous claim.”

The Examiner states that “[c]laims 1, 6 and 32 upon which claims 2, 7, and 34 respectively depend from are composition claims.” The Examiner further states that “[c]laim 2, which limits claim 1 to administration does not further limit claim 1 since claim 1 is directed to a composition and not to method of administration,” that “claim 7 does not further limit claim 6,” and that “claim 34 does not further limit claim 32 by limiting claim 32 to administration.”

In response, claims 2, 7, and 34 have been cancelled without prejudice to the further prosecution of these claims in a continuation application. Therefore, the Examiner is requested to remove these objections.

E. Rejections under 35 U.S.C. § 102

1. Scott (U.S. 3,621,097)

In the Office Action, claims 1-4, 6-20 and 24-32 were “rejected under 35 U.S.C. §102(b) as being anticipated by Scott (US 3,621,097).”

In making the 35 U.S.C.102(b) rejection of the present claims over Scott, the Examiner stated the following:

The instant claims are directed to sustained release formulation of metformin. The instant claims fail to recite specific doses or amounts of metformin. The instant claims recite the property and intended use of the formulation, and a future intended use of a composition is not critical in composition claims since no patentable weight is accorded to the composition by the intended use. A recitation of the property of the formulation does not accord patentable weight to a sustained release formulation of metformin over the sustained release formulation of the prior art. A property of a composition is inherent to that composition and said property cannot be separated from the formulation.

It is respectfully noted that the instant claims do not recite any specific dose that would exclude the metformin of dimethyl biguanide formulation of Scott from having the property of providing a therapeutic plasma level in a 24-hour period when Scott's formulation is administered to a subject or to treat mental illness.

The Examiner further states that "[t]he influence of food on the bioavailability of metformin is a property of metformin."

This rejection is traversed. It is respectfully submitted that the Examiner's failure to consider certain limitations of the claims (which the Examiner refers to as "intended use" of the formulations) is improper. The Examiner is reminded that "[t]here is nothing inherently wrong with defining some part of an invention in functional terms," and that "functional language does not, in and of itself, render a claim improper." MPEP 2173.05(g) (citing *In re Swinehart*, 169 USPQ 226 (CCPA 1971)). In addition, "[a] functional limitation must be evaluated and considered, just like any other limitation of the claim, for what it fairly conveys to a person of ordinary skill in the pertinent art in the context in which it is used." MPEP 2173.05(g).

As such, the Examiner must consider the following limitation of claim 1: "said formulation provides therapeutic plasma levels of said metformin to a human patient over a 24 hour period after administration to said patient," as well as the other functional limitations of the claims (including "said formulation providing an AUC which is increased by the presence of food as compared with administration in the fasting state").

Applicants acknowledge that the specification of Scott mentions that the “compounds can be prepared for oral administration in the form of simple or sustained-release tablets” (Column 4, lines 31-37). However, there is no teaching in Scott that the formulations provide therapeutic plasma levels of said metformin to a human patient over a 24 hours period as recited in claim 1. In addition, Scott fails to teach “said formulation providing an AUC which is increased by the presence of food as compared with administration in the fasting state” as recited in claims 1, 6, 8, 9, 12, 15, 18, 24, and 27. Further, Scott fails to teach “therapeutic levels of said metformin are attained in said human for 12 to 24 hours, and said dosage form does not exhibit a decrease in the bioavailability of metformin if taken with food” as recited in claim 31.

It cannot be stated that the formulations of Scott inherently provide therapeutic plasma levels over a 24 hour period as “[i]nherent anticipation requires that the missing descriptive material is ‘necessarily present,’ not merely probably or possibly present in the prior art.” See *Trintec Industries Inc. v. Top-U.S.A. Corp.*, 63 U.S.P.Q.2d 1597, 1599 (Fed. Cir. 2002) (citing *In re Robertson*, 49 USPQ2d 1949, 1950-51 (Fed Cir. 1999)). Further, “[i]nherency is established ‘if the natural result flowing from the operation as taught would result in the performance of the questioned function’” *Scaltech Inc. v. Retec/Tetra LLC*, 60 USPQ2d 1687, 1692 (Fed. Cir. 2001) (citing *Continental Can Co. v. Monsanto Co.*, 20 USPQ2d 1746, 1749 (Fed. Cir. 1991)). It is respectfully submitted that 24 hour therapeutic plasma levels as recited in claim 1 is not “necessarily present” in the Scott reference. In support of this position it is noted that Scott itself is completely lacking in any direction concerning how one would make a controlled-release metformin formulation. Although as noted by the Examiner in the Office Action, Example 4 describes preparation of a coated tablet that contains granules of dimethyl biguanide, it is respectfully submitted that there is no indication in Scott that this formulation is a controlled release formulation that provides 24 hour therapeutic plasma levels (nor is there any indication that this is even a controlled release formulation).

Further, it is respectfully submitted that the Examiners position that the influence of food on the bioavailability of the metformin is a property of metformin is incorrect. In support of

Applicants' position, a copy of the 52nd Edition of the Physician's Desk Reference (1998), section on the brand name immediate release metformin product, Glucophage®, is submitted herewith (as Exhibit A). Therein, at page 796, middle column, it is stated that "food decreases the extent and slightly delays the absorption of metformin, as shown by approximately a 40% lower peak concentration and 25% lower AUC in plasma and a 35 minute prolongation of time to peak plasma concentration following administration of a single 850 mg tablet of metformin with food, compared to the same tablet strength administered fasting." (emphasis added).

It is respectfully submitted that Exhibit A demonstrates that the bioavailability property of the claimed controlled-release dosage form when administered with food are not a property of the drug itself.

In view of the above remarks with respect to Scott, the Examiner is requested to remove this rejection.

2. Barry et al. (U.S. 5,055,306)

In the Office Action, claims 1-4, 6-20 and 24-32, and 34 were "rejected under 35 U.S.C. §102(b) as being as being anticipated by Barry et al. (US 5,055,306)."

In making the 35 U.S.C. §102(b) rejection of the present claims over Barry et al., the Examiner made similar statements with respect to Barry et al. as those above with respect to Scott.

In response to the Examiner's rejection over Barry et al., the Examiner is again reminded that the functional limitations of the claims must be considered, in particular the limitation of claims 1, 6, 8, 9, 12, 15, 18, 24, and 27, reciting "said formulation providing an AUC which is increased by the presence of food as compared with administration in the fasting state". It is respectfully submitted that Barry et al. fails in the very least to teach this limitation.

In addition, Barry et al. fails to teach the limitation of claim 31, reciting “said dosage form does not exhibit a decrease in the bioavailability of metformin if taken with food.”

In view of the above remarks with respect to Barry et al., the Examiner is respectfully requested to remove this rejection.

F. Rejections under 35 U.S.C. § 103

In the Office Action, claims 33, 35, and 36 were “rejected under 35 U.S.C. §103(a) as being as being unpatentable over Barry et al. (US 5,055,306).”

In making the 35 U.S.C. §103(a) rejection of the present claims over Barry et al., the Examiner states that “. . . it would have been obvious to one of ordinary skill in the art at the time the invention was made to administer the formulation of Barry to a subject in need thereof according to the disclosure of Barry,” and that “[o]ne having ordinary skill in the art would have been motivated to administer the formulation of Barry to a human diabetic subject with the expectation that the metformin will have the known effect of treating diabetes.”

In response it is respectfully submitted that Barry et al. fail to teach, hint or suggest, “orally administering on a once a day basis to a human diabetic patient in the presence of food a controlled release oral dosage form. . . such that . . . **a decrease in the bioavailability of metformin is not exhibited**” (emphasis added) as recited in claim 33. Further Barry et al. fail to teach, hint or suggest, “orally administering on a once a day basis in the presence of food . . . a controlled release dosage form . . . such that . . . (i) **a decrease in the bioavailability of metformin is not exhibited** relative to administration of the dosage form in the fasting state; or (ii) **an increase in the bioavailability of metformin is exhibited** relative to administration of the dosage form in the fasting state” (emphasis added) as recited in claim 35.

In view of the above remarks with respect to Barry et al., the Examiner is requested to remove this rejection.

III. Conclusion

It is respectfully submitted that in view of the actions taken and arguments presented, that this case is now in condition for allowance. An early and favorable action on the merits is earnestly solicited.

According to currently recommended Patent Office policy the Examiner is specifically authorized to contact the undersigned in the event that a telephonic interview will advance the prosecution of this application.

Respectfully submitted,


DAVIDSON, DAVIDSON & KAPPEL, LLC

By: _____

Robert J. Paradiso
Robert J. Paradiso
Reg. No. 41,240

By David Y. Koppel
Reg. No. 45,991

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940



PHYSICIANS'

DESK

REFERENCE®

PRODUCT INFORMATION

DAILY DOSAGE OF DURICEF® SUSPENSION

Child's Weight				
lbs	kg	125 mg/5 mL	250 mg/5 mL	500 mg/5 mL
10	4.5	1 tsp	—	—
20	9.1	2 tsp	1 tsp	—
30	13.6	3 tsp	1½ tsp	—
40	18.2	4 tsp	2 tsp	1 tsp
50	22.7	5 tsp	2½ tsp	1½ tsp
60	27.3	6 tsp	3 tsp	1½ tsp
70 & above	31.8+	—	—	2 tsp

Reconstitution Directions for Oral Suspension

Bottle Size	Reconstitution Directions
100 mL	Suspend in a total of 67 mL water. Method: Tap bottle lightly to loosen powder. Add 67 mL of water in two portions. Shake well after each addition.
75 mL	Suspend in a total of 51 mL water. Method: Tap bottle lightly to loosen powder. Add 51 mL of water in two portions. Shake well after each addition.
50 mL	Suspend in a total of 34 mL water. Method: Tap bottle lightly to loosen powder. Add 34 mL of water in two portions. Shake well after each addition.

After reconstitution, store in refrigerator. Shake well before using. Keep container tightly closed. Discard unused portion after 14 days.

skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. In the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage of DURICEF® should be administered for at least 10 days.

See chart for total daily dosage for children.

(See first table above)

In patients with renal impairment, the dosage of cefadroxil monohydrate should be adjusted according to creatinine clearance rates to prevent drug accumulation. The following schedule is suggested. In adults, the initial dose is 1000 mg of DURICEF (cefadroxil monohydrate, USP) and the maintenance dose (based on the creatinine clearance rate (mL/min/1.73 M²)) is 500 mg at the time intervals listed below.

Creatinine Clearances	Dosage Interval
0-10 mL/min	36 hours
10-25 mL/min	24 hours
25-50 mL/min	12 hours

Patients with creatinine clearance rates over 50 mL/min may be treated as if they were patients having normal renal function.

(See second table above)

HOW SUPPLIED

DURICEF® (cefadroxil monohydrate, USP) 500 mg Capsules: opaque, maroon and white hard gelatin capsules, imprinted with "PPP" and "784" on one end and with "DURICEF" and "500 mg" on the other end. Capsules are supplied as follows:

NDC 0087-0784-07	Bottle of 20
NDC 0087-0784-46	Bottle of 50
NDC 0087-0784-42	Bottle of 100
NDC 0087-0784-44	10 strips of 10 individually labeled blisters with 1 capsule per blister

Store at controlled room temperature (15°-30°C).

DURICEF® (cefadroxil monohydrate, USP) 1 gram Tablets: white to off white, top bisected, oval shaped, imprinted with "PPP" on one side of the bisect and "785" on the other side of the bisect. Tablets are supplied as follows:

NDC 0087-0785-43	Bottle of 50
NDC 0087-0785-42	Bottle of 100
NDC 0087-0785-44	10 strips of 10 individually labeled blisters with 1 tablet per blister
NDC 0087-0785-45	4 packs of 10 individually labeled blisters with 1 tablet per blister

Store at controlled room temperature (15°-30°C).

DURICEF® for Oral Suspension is orange-pineapple flavored, and is supplied as follows:

125 mg/5 mL	NDC 0087-0786-42	50 mL Bottle
	NDC 0087-0786-41	100 mL Bottle
250 mg/5 mL	NDC 0087-0782-42	50 mL Bottle
	NDC 0087-0782-41	100 mL Bottle
500 mg/5 mL	NDC 0087-0783-42	50 mL Bottle
	NDC 0087-0783-05	75 mL Bottle
	NDC 0087-0783-41	100 mL Bottle

Prior to reconstitution: Store at controlled room temperature (15°-30°C).

U.S. Patent Nos. 4,160,863
4,504,657

REFERENCES

1. National Committee for Clinical Laboratory Standards, Approved Standard, Performance Standards for Antimicrobial Disk Susceptibility Test, 4th Edition, Vol. 10 (7): M2-A4, Villanova, PA, April, 1990.
2. National Committee for Clinical Laboratory Standards, Approved Standard: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 2nd Edition, Vol. 10 (8): M7-A2, Villanova, PA, April, 1990.

0783DIM-05

Revised February 1997

E3-B001-2-97


Shown in Product Identification Guide, page 307

GLUCOPHAGE®

[glu-k6-faj]
(metformin hydrochloride tablets)

DESCRIPTION

GLUCOPHAGE (metformin hydrochloride tablets) is an oral antihyperglycemic drug used in the management of non-insulin-dependent diabetes mellitus (NIDDM). Metformin hydrochloride (N,N-dimethylimidodicyanimidic diamide hydrochloride) is not chemically or pharmacologically related to the oral sulfonylureas. The structural formula is as shown:



Metformin-hydrochloride is a white to off-white crystalline compound with a molecular formula of C₄H₁₁N₅ · HCl and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether or chloroform. The pK_a of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68.

GLUCOPHAGE tablets contain 500 mg and 850 mg of metformin hydrochloride. In addition, each tablet contains the following inactive ingredients: povidone, magnesium stearate and hydroxypropyl methylcellulose (hypromellose) coating.

CLINICAL PHARMACOLOGY

Antidiabetic Activity

GLUCOPHAGE is an antihyperglycemic agent which improves glucose tolerance in NIDDM subjects, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from those of sulfonylureas. GLUCOPHAGE decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization). Unlike sulfonylureas, GLUCOPHAGE does not

Continued on next page

Consult 1998 PDR® supplements and future editions for revisions

3' DESK REFERENCE

hods, dilution procedure, control organisms. The MIC values in the Staphylococcus aureus TCC 25922, the MIC and 16.0 µg/mL. The MIC range should be

hydrate, USP) is indicated for infection caused by organisms in the following: 1 by E. coli, P. mirabilis, and other organisms caused by streptococci.

used by Group A streptococci, the usual drug of choice for streptococcal infection. Duration of streptococcal infection should be established by subsequent prevention of infection (present).

ility tests should be performed. Renal function studies should be performed.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

hydrate, USP) is contraindicated in patients with a known allergy to the cephalosporins.

Glucophage—Cont.

produce hypoglycemia in either diabetic or nondiabetic subjects (except in special circumstances, see PRECAUTIONS) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.

In a double-blind, placebo-controlled, multicenter U.S. clinical trial involving obese NIDDM patients whose hyperglycemia was not adequately controlled with dietary management alone (baseline fasting plasma glucose [FPG] of approximately 240 mg/dL), treatment with GLUCOPHAGE (up to 2.55 g/day) for 29 weeks resulted in significant mean net reduction in fasting and postprandial plasma glucose (PPG) and HbA_{1c} of 59 mg/dL, 83 mg/dL, and 1.8%, respectively, compared to placebo group (see Table 1).

Table 1. GLUCOPHAGE vs Placebo
Summary of Mean Changes from Baseline* in
Plasma Glucose

	GLUCOPHAGE (n=141)	Placebo (n=145)	P-Value
FPG (mg/dL)			
Baseline	241.5	237.7	NS
Change at FINAL VISIT	-53.0	6.3	0.001 **
Hemoglobin A _{1c} (%)			
Baseline	8.4	8.2	NS
Change at FINAL VISIT	-1.4	0.4	0.001 **
Body Weight (lbs)			
Baseline	201.0	206.0	NS
Change at FINAL VISIT	-1.4	-2.4	NS

* All patients on diet therapy at Baseline.
** Statistically significant

Monotherapy with GLUCOPHAGE may be effective in patients who have not responded to sulfonylureas or who have only a partial response to sulfonylureas or who have ceased to respond to sulfonylureas. In such patients, if adequate glycemic control is not attained with GLUCOPHAGE monotherapy, the combination of GLUCOPHAGE and a sulfonylurea may have a synergistic effect, since both agents act to improve glucose tolerance by different but complimentary mechanisms.

A 29-week, double-blind, placebo-controlled study of GLUCOPHAGE and glyburide, alone and in combination, was conducted in obese NIDDM patients who had failed to achieve adequate glycemic control while on maximum doses of glyburide (baseline FPG of approximately 250 mg/dL) (see Table 2). Patients randomized to continue on glyburide experienced worsening of glycemic control, with mean increases in FPG, PPG and HbA_{1c} of 14 mg/dL, 3 mg/dL and 0.2%, respectively. In contrast, those randomized to GLUCOPHAGE (metformin hydrochloride tablets) (up to 2.5 g/day) did not experience a deterioration in glycemic control, but rather a slight improvement, with mean reductions in FPG, PPG and HbA_{1c} of 1 mg/dL, 6 mg/dL and 0.4%, respectively. The combination of GLUCOPHAGE and glyburide was synergistic in reducing FPG, PPG and HbA_{1c} levels by 63 mg/dL, 65 mg/dL, and 1.7%, respectively. Compared to the results of glyburide treatment alone, the net differences with combined treatment were -77 mg/dL, -68 mg/dL and -1.9%, respectively (see Table 2). [See table above]

The magnitude of the decline in fasting blood glucose concentration following the institution of GLUCOPHAGE (metformin hydrochloride tablets) therapy is proportional to the level of fasting hyperglycemia. Non-insulin-dependent diabetics with higher fasting glucose concentrations will experience greater declines in plasma glucose and glycosylated hemoglobin.

GLUCOPHAGE has a modest favorable effect on serum lipids, which are often abnormal in NIDDM patients. In clinical studies, particularly when baseline levels were abnormally elevated, GLUCOPHAGE, alone or in combination with a sulfonylurea, lowered mean fasting serum triglycerides, total cholesterol and LDL cholesterol levels and had no adverse effects on other lipid levels (see Table 3). [See table above]

In contrast to sulfonylureas, body weight of individuals on GLUCOPHAGE tends to remain stable or may even decrease somewhat (see Table 1 and 2).

In summary, metformin-treated patients showed significant improvement in all parameters of glycemic control (FPG, PPG and HbA_{1c}), stabilization or decrease in body weight, and a tendency to improvement in the lipid profile, particularly when baseline values are abnormally elevated.

Pharmacokinetics

Absorption and Bioavailability:

The absolute bioavailability of a 500 mg metformin hydrochloride tablet given under fasting conditions is approxi-

Table 2. Combined GLUCOPHAGE/Glyburide (Comb) vs Glyburide (Glyb) or Glucophage (GLU) Monotherapy: Summary of Mean Changes from Baseline* in Plasma Glucose, HbA_{1c} and Body Weight, at Final Visit (29-week study)

	Comb (n=213)	Glyb (n=209)	GLU (n=210)	Glyb vs Comb	P-values GLU vs Comb
Fasting Plasma					
Glucose (mg/dL)					
Baseline	250.5	247.5	253.9	NS	NS
Change at FINAL VISIT	-63.5	13.7	-0.9	0.001 **	0.001 **
Hemoglobin A _{1c} (%)					
Baseline	8.8	8.5	8.9	NS	NS
Change at FINAL VISIT	-1.7	0.2	-0.4	0.001 **	0.001 **
Body Weight (lbs)					
Baseline	202.2	203.0	204.0	NS	NS
Change at FINAL VISIT	0.9	-0.7	-8.4	0.011 **	0.001 **

* All patients of glyburide, 20 mg/day, at Baseline
** Statistically significant

Table 3. Summary of Mean Percent Reduction of Major Serum Lipid Variables at Final Visit (29-week study)

	Glucophage vs. Placebo (% Change from Baseline)		Combined Glucophage/Glyburide vs. Monotherapy (% Change from Baseline)	
	Glucophage (n=141)	Placebo (n=145)	Glucophage (n=210)	Glyburide/ Glyburide (n=213)
Total				
Cholesterol	-5%*	1%	-2%	-4%**
Total				
Triglycerides	-16%	1%	-3%**	-8%**
LDL				
Cholesterol	-8%*	1%	-4%**	-6%**
HDL				
Cholesterol	2%	-1%	5%	3%

* <0.05 vs. Placebo
** <0.05 vs. Glyburide

mately 50-60%. Studies using single oral doses of metformin tablets of 500 mg and 1500 mg, and 850 mg to 2550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Food decreases the extent and slightly delays the absorption of metformin, as shown by approximately a 40% lower peak concentration and 25% lower AUC in plasma and a 35 minute prolongation of time to peak plasma concentration following administration of a single 850 mg tablet of metformin with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown.

Distribution:

The apparent volume of distribution (V/F) of metformin following single oral doses of 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins in contrast to sulfonylureas which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of GLUCOPHAGE (metformin hydrochloride tablets), steady state plasma concentrations of metformin are reached within 24-48 hours and are generally <1 µg/mL. During controlled clinical trials, maximum metformin plasma levels did not exceed 5 µg/mL, even at maximum doses.

Metabolism and Elimination:

Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion. Renal clearance (see Table 4) is approximately 3.5 times greater than creatinine clearance which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.

Special Populations:

NIDDM Subjects:

In the presence of normal renal function, there are no differences between single or multiple dose pharmacokinetics

of metformin between diabetics and nondiabetics (see Table 4), nor is there any accumulation of metformin in group at usual clinical doses.

Renal Insufficiency:

In subjects with decreased renal function (based on serum creatinine clearance), the plasma and blood levels of metformin are prolonged and the renal clearance decreased in proportion to the decrease in creatinine clearance (see Table 4).

Hepatic Insufficiency:

No pharmacokinetic studies have been conducted in subjects with hepatic insufficiency.

Geriatrics:

Limited data from controlled pharmacokinetic studies in metformin in healthy elderly subjects suggest that plasma clearance is decreased, the half-life is prolonged, and C_{max} is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by change in renal function (see Table 4). [See table at top of next page]

Pediatrics:

No pharmacokinetic studies have been conducted in pediatric subjects.

Gender:

Metformin pharmacokinetic parameters did not differ significantly in diabetic and nondiabetic subjects when analyzed according to gender (males=19, females=16). Early, in controlled clinical studies in patients with NIDDM, the antihyperglycemic effect of GLUCOPHAGE (metformin hydrochloride tablets) was comparable in males and females.

Race:

No studies of metformin pharmacokinetics controlled for race have been performed. In controlled clinical studies of GLUCOPHAGE in patients with NIDDM, the antihyperglycemic effect was comparable in white (n=11), blacks (n=51) and hispanics (n=24).

INDICATIONS AND USE

GLUCOPHAGE (metformin hydrochloride tablets) monotherapy, is indicated as an adjunct to diet in the management of blood glucose in patients with NIDDM whose blood glucose cannot be satisfactorily managed on diet alone.

- ^a-All doses given fasting except the first 18 doses of the multiple dose studies;
- ^b-Peak plasma concentration;
- ^c-Time to peak plasma concentration;
- ^d-SD=single dose;
- ^e-Combined results (average means) of five studies: mean age 32 years (range 23-59 yrs).
- ^f-Kinetic study done following dose 19, given fasting.
- ^g-Elderly subjects, mean age 71 years (range 65-81 years).
- ^h-CL_{CR}=creatinine clearance normalized to body surface area of 1.73 m².

Consult 1998 PDR® supplements and future editions for revisions

Glucophage—Cont.

Impaired hepatic function—Since impaired hepatic function has been associated with some cases of lactic acidosis, GLUCOPHAGE should generally be avoided in patients with clinical or laboratory evidence of hepatic disease.

Vitamin B₁₂ levels—A decrease to subnormal levels of previously normal serum vitamin B₁₂ levels, without clinical manifestations, is observed in approximately 7% of patients receiving GLUCOPHAGE in controlled clinical trials of 29 weeks duration. Such decrease, possibly due to interference with B₁₂ absorption from the B₁₂-intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of GLUCOPHAGE (metformin hydrochloride tablets) or vitamin B₁₂ supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on GLUCOPHAGE and any apparent abnormalities should be appropriately investigated and managed (see Laboratory Tests).

Certain individuals (those with inadequate vitamin B₁₂ or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B₁₂ levels. In these patients, routine serum vitamin B₁₂ measurements at two- to three-year intervals may be useful.

Change in clinical status of previously controlled diabetic—A diabetic patient previously well controlled on GLUCOPHAGE who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate and metformin levels. If acidosis of either form occurs, GLUCOPHAGE must be stopped immediately and other appropriate corrective measures initiated (see also WARNINGS).

Hypoglycemia—Hypoglycemia does not occur in patients receiving GLUCOPHAGE alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas) or ethanol. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs.

Loss of control of blood glucose—When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold GLUCOPHAGE and temporarily administer insulin. GLUCOPHAGE may be reinstituted after the acute episode is resolved.

The effectiveness of oral antidiabetic drugs in lowering blood glucose to a targeted level decreases in many patients over a period of time. This phenomenon, which may be due to progression of the underlying disease or to diminished responsiveness to the drug, is known as "secondary failure," to distinguish it from primary failure in which the drug is ineffective during initial therapy. Should secondary failure occur with GLUCOPHAGE or sulfonylurea monotherapy, combined therapy with GLUCOPHAGE (metformin hydrochloride tablets) and sulfonylurea may result in a response. Should secondary failure occur with combined GLUCOPHAGE/sulfonylurea therapy, it may be necessary to initiate insulin therapy.

Information for Patients:

Patients should be informed of the potential risks and advantages of GLUCOPHAGE and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose, glycosylated hemoglobin, renal function and hematologic parameters.

The risks of lactic acidosis, its symptoms, and conditions that predispose to its development, as noted in the WARNINGS and PRECAUTIONS sections should be explained to patients. Patients should be advised to discontinue GLUCOPHAGE immediately and to promptly notify their health practitioner if unexplained hyperventilation, myalgia, malaise, unusual somnolence or other nonspecific symptoms occur. Once a patient is stabilized on any dose level of GLUCOPHAGE, gastrointestinal symptoms, which are common during initiation of therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.

Patients should be counselled against excessive alcohol intake, either acute or chronic, while receiving GLUCOPHAGE.

GLUCOPHAGE alone does not usually cause hypoglycemia, although it may occur when GLUCOPHAGE is used in conjunction with oral sulfonylureas. When initiating combination therapy, the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients.

(See Patient Labeling Printed Below)

Laboratory Tests:

Response to all diabetic therapies should be monitored by periodic measurements of fasting blood glucose and glycosylated hemoglobin levels, with a goal of decreasing these levels toward the normal range. During initial dose titration, fasting glucose can be used to determine the therapeutic response. Thereafter, both glucose and glycosylated hemoglobin should be monitored. Measurements of glycosylated hemoglobin may be especially useful for evaluating long-term control (see also DOSAGE AND ADMINISTRATION).

Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red blood cell indices) and renal function (serum creatinine) should be performed, at least on an annual basis. While megaloblastic anemia has rarely been seen with GLUCOPHAGE (metformin hydrochloride tablets) therapy, if this is suspected, vitamin B₁₂ deficiency should be excluded.

Drug Interactions:

Glyburide: In a single-dose interaction study in NIDDM subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. Decreases in glyburide AUC and C_{max} were observed, but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION, Concomitant Glucophage and Oral Sulfonylurea Therapy).

Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide increased the metformin plasma and blood C_{max} by 22% and blood AUC by 15%, without any significant change in metformin renal clearance. When administered with metformin, the C_{max} and AUC of furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin and furosemide when co-administered chronically.

Nifedipine: A single-dose, metformin-nifedipine drug interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin C_{max} and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. T_{max} and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine.

Cationic Drugs: Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, trimethoprim, and vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Such interaction between metformin and oral cimetidine has been observed in normal healthy volunteers in both single- and multiple-dose, metformin-cimetidine drug interaction studies, with a 60% increase in peak metformin plasma and whole blood concentrations and a 40% increase in plasma and whole blood metformin AUC. There was no change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine pharmacokinetics. Although such interactions remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of GLUCOPHAGE and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.

Other: Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include thiazide and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving GLUCOPHAGE, the patient should be closely observed to maintain adequate glycemic control.

In healthy volunteers, the pharmacokinetics of metformin and propranolol and metformin and ibuprofen were not affected when co-administered in single-dose interaction studies.

Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as compared to the sulfonylureas, which are extensively bound to serum proteins.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately three times the maximum recommended human daily dose on a body surface area basis. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential

observed with metformin in male rats. No evidence of increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day. No evidence of a mutagenic potential to metformin was found in the Ames test (*S. typhimurium*), bacterial mutagenicity test (mouse lymphoma cells), chromosomal aberration test (human lymphocytes), or *in-vivo* micronucleus test (mouse bone marrow).

Fertility of male or female rats was unaffected by administration at doses as high as 600 mg/kg/day, approximately two times the maximum recommended human daily dose on a body surface area basis.

Pregnancy:

Teratogenic effects:

Pregnancy Category B. Safety in pregnant women has been established. Metformin was not teratogenic in rabbits at doses up to 600 mg/kg/day, or about 1.5 times the maximum recommended human daily dose on a body surface area basis. Determination of fetal concentration demonstrated a partial placental barrier to metformin. Animal reproduction studies are not always predictive of human response, any decision to use this drug during pregnancy should be based on a weighing of potential risks against the benefits and risks.

Because recent information suggests that abnormal glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, the use of metformin during pregnancy should be based on a consensus among experts that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nursing Mothers:

Studies in lactating rats show that metformin is excreted into milk and reaches levels comparable to those in plasma. Similar studies have not been conducted in humans. Therefore, caution should be exercised in such patients. A decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use:

Safety and effectiveness in pediatric patients have not been established. Studies in maturity-onset diabetes (MODY) have not been conducted.

Geriatric Use:

Controlled clinical studies of GLUCOPHAGE (metformin hydrochloride tablets) did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other clinical experience has not identified differences in response between the elderly and younger patients. GLUCOPHAGE is known to be substantially excreted by the kidney, and because the risk of serious adverse reactions to drugs is greater in patients with impaired renal function, GLUCOPHAGE should only be used in patients with normal renal function.

CONTRAINDICATIONS, CLINICAL PHARMACOLOGY, Pharmacokinetics. Because aging is associated with reduced renal function, GLUCOPHAGE should be used with caution as age increases. Care should be taken in selection and should be based on careful and regular monitoring of renal function. Generally, elderly patients should be titrated to the maximum dose of GLUCOPHAGE (see DOSAGE AND ADMINISTRATION).

ADVERSE REACTIONS

Lactic Acidosis: See WARNINGS, PRECAUTIONS, OVERDOSAGE Sections.

Gastrointestinal Reactions: Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal bloating, flatulence, and anorexia) are the most common reactions to GLUCOPHAGE and are approximately 30% more frequent in patients on GLUCOPHAGE monotherapy than in untreated patients, particularly during initiation of GLUCOPHAGE therapy. These symptoms are self-limiting and resolve spontaneously during continued treatment. Occasionally, temporary dose reduction may be useful. In controlled trials, GLUCOPHAGE was discontinued due to gastrointestinal reactions in approximately 1% of patients.

Because gastrointestinal symptoms during therapy appear to be dose-related, they may be avoided by gradual dose escalation and by having patients take GLUCOPHAGE (metformin hydrochloride tablets) with meals (see DOSAGE AND ADMINISTRATION). Because significant diarrhea and/or vomiting may occur, dehydration and prerenal azotemia, undetected in some instances, GLUCOPHAGE should be temporarily withheld.

For patients who have been stabilized on GLUCOPHAGE, nonspecific gastrointestinal symptoms should not be attributed to therapy unless intercurrent illness or other factors have been excluded.

Special Senses: During initiation of GLUCOPHAGE therapy, approximately 3% of patients may complain of a pleasant or metallic taste, which usually resolves spontaneously.

Dermatologic Reactions: The incidence of rash in controlled clinical trials was comparable to that in GLUCOPHAGE monotherapy and to sulfonylurea monotherapy.

PRODUCT INFORMATION

male rats. However, uterine polyps were observed in female rats given 30 mg/kg/day of metformin. In patients on GLUCOPHAGE monotherapy and 6% of patients on GLUCOPHAGE/sulfonylurea therapy developed subnormal serum vitamin B₁₂ levels; serum B₁₂ levels did not decrease significantly. However, only 10% of patients on GLUCOPHAGE/sulfonylurea therapy had megaloblastic anemia. There have been reports with long-term administration (none during U.S. clinical studies) of an increased incidence of neuropathy has been observed with 600 mg/kg/day of metformin. Therefore, serum B₁₂ levels should be appropriately monitored and periodic parenteral B₁₂ supplementation considered on a case-by-case basis.

GLUCOPHAGE AND DEPENDENCE

GLUCOPHAGE possesses no pharmacodynamic properties, primary or secondary, which could be expected to result in dependence on the drug as a recreational drug or addiction.

GLUCOPHAGE

GLUCOPHAGE has not been seen with ingestion of up to 85 mg/kg of metformin. However, lactic acidosis has occurred in such circumstances (see WARNINGS). Metformin is excreted with a clearance of up to 170 mL/min under steady-state conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom overdosage is suspected.

GLUCOPHAGE AND ADMINISTRATION

GLUCOPHAGE is a fixed-dose regimen for the management of hyperglycemia in patients with diabetes mellitus with GLUCOPHAGE or other antidiabetic agent. Dosage of GLUCOPHAGE should be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily dose of 2550 mg. GLUCOPHAGE should be given in divided doses with meals and should be started at a low dose with gradual dose escalation, as described below, to minimize gastrointestinal side effects and to permit the patient to achieve the minimum dose required for adequate control of the patient.

For treatment initiation and dose titration (see below, STARTING DOSE), fasting plasma glucose should be determined to determine the therapeutic response to GLUCOPHAGE and identify the minimum effective dose for the patient. Thereafter, glycosylated hemoglobin should be determined at intervals of approximately three months. The therapeutic goal should be to decrease both fasting plasma glucose and glycosylated hemoglobin levels to normal or near normal by using the lowest effective dose of GLUCOPHAGE either when used as monotherapy or in combination with sulfonylurea.

Monitoring of blood glucose and glycosylated hemoglobin should permit detection of primary failure, i.e., inadequate control of blood glucose at the maximum recommended dose of GLUCOPHAGE, and secondary failure, i.e., loss of an adequate blood glucose lowering response after an initial period of effectiveness.

When administration of GLUCOPHAGE (metformin hydrochloride tablets) may be sufficient during periods of control in patients usually well-controlled on sulfonylurea therapy.

Starting Dose: In patients with no clinically significant responses are not seen at 500 mg per day. However, a lower recommended starting dose and gradually increased dosage is advised to minimize gastrointestinal symptoms.

GLUCOPHAGE 500 mg Tablets: The recommended starting dose of GLUCOPHAGE 500 mg tablets is 500 mg given with the morning and evening meals. The dosage should be made in increments of one tablet every week given in divided doses, up to a maximum of 2000 mg per day (e.g., 1000 mg b.i.d. with morning and evening meals). If a 2500 mg daily dose is required, the patient may be better tolerated given t.i.d. with meals.

GLUCOPHAGE 850 mg Tablets: The recommended starting dose of GLUCOPHAGE 850 mg tablets is 850 mg given with the morning meal. Dosage increments should be made in increments of one tablet every week given in divided doses, up to a maximum of 2550 mg per day. The usual maintenance dose is 850 mg given with the morning and evening meals. When necessary, the dosage may be given 850 mg t.i.d. with meals.

Transfer from Other Antidiabetic Therapy: When transferring patients from standard oral hypoglycemic agents other than chlorpropamide to GLUCOPHAGE, a gradual reduction in the dose of the other agent is necessary. While transfer from chlorpropamide, care should be exercised during the first two weeks because of the prolonged retention of chlorpropamide in the body, leading to overlapping effects and possible hypoglycemia.

GLUCOPHAGE and Oral Sulfonylurea Therapy: When transferred from oral sulfonylurea therapy to GLUCOPHAGE, the dose of the sulfonylurea should be gradually reduced over a period of four weeks to avoid hypoglycemia.

Warnings: The incidence of lactic acidosis was comparable to sulfonylurea therapy and to sulfonylurea therapy.

has occurred. Clinical and pharmacokinetic drug-drug interaction data are currently available only for metformin plus glyburide (glibendamide). Published clinical information exists for the use of metformin with either chlorpropamide, tolbutamide or glipizide. No published clinical information exists regarding concomitant use of metformin with acetohexamide or tolazamide.

With concomitant GLUCOPHAGE and sulfonylurea therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug. However, attempts should be made to identify the minimum effective dose of each drug to achieve this goal. With concomitant GLUCOPHAGE and sulfonylurea therapy, the risk of hypoglycemia associated with sulfonylurea therapy continues and may be increased. Appropriate precautions should be taken. (See Package Insert of the respective sulfonylurea).

If patients have not satisfactorily responded to one to three months of concomitant therapy with the maximum dose of GLUCOPHAGE and the maximum dose of an oral sulfonylurea, institution of insulin therapy and discontinuation of these oral agents should be considered.

Specific Patient Populations:

GLUCOPHAGE is not recommended for use in pregnancy or for use in pediatric patients.

The initial and maintenance dosing of GLUCOPHAGE should be conservative in patients with advanced age, due to the potential for decreased renal function in this population. Any dosage adjustment should be based on a careful assessment of renal function. Generally, elderly patients should not be titrated to the maximum dose of GLUCOPHAGE.

In debilitated or malnourished patients, the dosing should also be conservative and based on a careful assessment of renal function.

HOW SUPPLIED

GLUCOPHAGE® (brand of metformin hydrochloride tablets) is supplied as white, round, white to off-white, film-coated tablets, available in the following strengths:

500 mg . . . Bottles of 100 . . . NDC 0087-6060-05
850 mg . . . Bottles of 100 . . . NDC 0087-6070-05

GLUCOPHAGE 500 mg tablets are debossed with BMS 6060 around the periphery of the tablet on one side and 500 across the face of the other side. GLUCOPHAGE 850 mg tablets are debossed with BMS 6070 around the periphery of the tablet on one side and 850 across the face of the other side.

Storage

Store between 15°-30°C (59°-86°F).

PATIENT INFORMATION ABOUT

GLUCOPHAGE® (metformin hydrochloride tablets)

500 mg and 850 mg

WARNING: A small number of people who have taken Glucophage have developed a serious condition called lactic acidosis. Properly functioning kidneys are needed to help prevent lactic acidosis. Most people with kidney problems should not take Glucophage. (See Question Nos. 7-11)

Q1: Why do I need to take GLUCOPHAGE?
Your doctor has prescribed GLUCOPHAGE (GLUCOPHAGE) to treat your type II diabetes. This is also known as non-insulin-dependent diabetes mellitus (NIDDM).

Q2: What is type II diabetes?
People with diabetes are not able to make enough insulin and/or respond normally to the insulin their body does make. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems including kidney damage, amputations and blindness. Diabetes is also closely linked to heart disease. The main goal of treating diabetes is to lower your blood sugar to a normal level.

Q3: How is type II diabetes usually controlled?
High blood sugar can be lowered by diet and exercise, by a number of oral medications and by insulin injections. Before taking GLUCOPHAGE you should first try to control your diabetes by exercise and weight loss. Even if you are taking GLUCOPHAGE, you should still exercise and follow the diet recommended for your diabetes.

Q4: Does GLUCOPHAGE work differently from other glucose-control medications?
Yes it does. Until GLUCOPHAGE was introduced, all the available oral glucose-control medications were from the same chemical group called sulfonylureas. These drugs lower blood sugar primarily by causing more of the body's own insulin to be released. GLUCOPHAGE (metformin hydrochloride tablets) lowers the amount of sugar in your blood by helping your body respond better to its own insulin. GLUCOPHAGE does not cause your body to produce more insulin. Therefore, GLUCOPHAGE rarely causes hypoglycemia (low blood sugar) and it doesn't usually cause weight gain.

Q5: What happens if my blood sugar is still too high?
When blood sugar cannot be lowered enough by either GLUCOPHAGE (metformin hydrochloride tablets) or a sulfonylurea, the two medications may be effective taken together.

However, if you are unable to maintain your blood sugar with diet, exercise and glucose-control medication taken orally, then your doctor may prescribe injectable insulin to control your diabetes.

Q6: Can GLUCOPHAGE cause side effects?
GLUCOPHAGE, like all blood-sugar lowering medications, can cause side effects in some patients. Most of these side effects are minor and will go away after you've taken GLUCOPHAGE for a while. However, there are also serious, but rare side effects related to GLUCOPHAGE (see below).

Q7: What kind of side effects can GLUCOPHAGE cause?
If side effects occur, they usually occur during the first few weeks in therapy. They are normally minor ones such as diarrhea, nausea and upset stomach. Taking your GLUCOPHAGE with meals can help reduce these side effects. Although these side effects are likely to go away, call your doctor if you have severe discomfort or if these effects last for more than a few weeks. Some patients may need to have their dose lowered or stop taking GLUCOPHAGE, either temporarily or permanently. Although these problems occur in up to one-third of patients when they first start taking GLUCOPHAGE, you should tell your doctor if the problems come back or start later on during the therapy.

About three out of one hundred people report having a temporary unpleasant or metallic taste when they start taking GLUCOPHAGE.

Q8: Are there any serious side effects that GLUCOPHAGE can cause?
GLUCOPHAGE rarely causes serious side effects. The most serious side effect that GLUCOPHAGE can cause is called lactic acidosis.

Q9: What is lactic acidosis and can it happen to me?
Lactic acidosis is caused by a buildup of lactic acid in the blood. Lactic acidosis associated with GLUCOPHAGE is rare and has occurred mostly in people whose kidneys were not working normally. Lactic acidosis has been reported in about one in 33,000 patients taking GLUCOPHAGE over the course of a year. Although rare, if lactic acidosis does occur, it can be fatal in up to half the cases.

It is also important for your liver to be working normally when you take GLUCOPHAGE. Your liver helps remove lactic acid from your bloodstream. Your doctor will monitor your diabetes and may perform blood tests on you from time to time to make sure your kidneys and your liver are functioning normally.

There is no evidence that GLUCOPHAGE causes harm to the kidneys or liver.

Q10: Are there other risk factors for lactic acidosis?
Your risk of developing lactic acidosis from taking GLUCOPHAGE is very low as long as your kidneys and liver are healthy. However, some factors can increase your risk because they can affect kidney and liver function. You should not take GLUCOPHAGE if:

- You have chronic kidney or liver problems
- You drink alcohol excessively (all the time or short-term "binge" drinking)
- You are seriously dehydrated (have lost a large amount of body fluids)
- You are going to have certain x-ray procedures with injectable contrast agents
- You are going to have surgery
- You develop a serious condition such as a heart attack, severe infection, or a stroke.

Q11: What are the symptoms of lactic acidosis?
Some of the symptoms include: feeling very weak, tired or uncomfortable; unusual muscle pain, trouble breathing, unusual or unexpected stomach discomfort, feeling cold, feeling dizzy or lightheaded, or suddenly developing slow or irregular heartbeat.

If you notice these symptoms, or if your medical condition has suddenly changed, stop taking GLUCOPHAGE and call your doctor right away. Lactic acidosis is a medical emergency that must be treated in a hospital.

Q12: What does my doctor need to know to decrease my risk of lactic acidosis?
Tell your doctor if you have an illness that results in severe vomiting, diarrhea and/or fever, or if your intake of fluids is significantly reduced. These situations can lead to severe dehydration, and it may be necessary to stop taking GLUCOPHAGE temporarily.

You should let your doctor know if you are going to have any surgery or specialized x-ray procedures that require injection of contrast agents. GLUCOPHAGE therapy will need to be stopped temporarily in such instances.

Q13: Can I take GLUCOPHAGE with other medications?
Remind your doctor that you are taking GLUCOPHAGE when any new drug is prescribed or a change is made in how you take a drug already prescribed. GLUCOPHAGE may interfere with the way some drugs work and some drugs may interfere with the action of GLUCOPHAGE.

Glucophage—Cont.

Q14: What if I become pregnant while taking GLUCOPHAGE?

Tell your doctor if you plan to become pregnant or have become pregnant. As with other oral glucose-control medications, you should not take GLUCOPHAGE during pregnancy.

Usually your doctor will prescribe insulin while you are pregnant. As with all medications, you and your doctor should discuss the use of GLUCOPHAGE if you are nursing a child.

Q15: Are there other risks associated with GLUCOPHAGE?

There is some evidence that any oral diabetes drug may increase the risk of heart problems. Experts are not sure what the real risk for heart problems, if any, from taking oral diabetes medicine.

Q16: How do I take GLUCOPHAGE?

Your doctor will tell you how many GLUCOPHAGE tablets to take and how often. This should also be printed on the label of your prescription. You will probably be started on a low dose of GLUCOPHAGE and your dosage will be increased gradually until your blood sugar is controlled.

Q17: Where can I get more information about GLUCOPHAGE?

This leaflet is a summary of the most important information about GLUCOPHAGE. If you have any questions or problems, you should talk to your doctor or other healthcare provider about type II diabetes as well as GLUCOPHAGE and its side effects. There is also a leaflet (package insert) written for health professionals that your pharmacist can let you read.

Glucophage is a registered trademark of LIPHA s.a.

Licensed to Bristol-Myers Squibb Company.

6060 DIM-01

Revised: June 1996

51-005135-00

Shown in Product Identification Guide, page 307

MAXIPIME®


(maxipime)

(Cefepime Hydrochloride) for Injection
For Intravenous or Intramuscular Use

CAUTION: Federal law prohibits dispensing without prescription.

DESCRIPTION

Cefepime hydrochloride is a semi-synthetic, broad spectrum, cephalosporin antibiotic for parenteral administration. The chemical name is 1-[[[(6R,7R)-7-[(2-amino-4-thiazolyl)-glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-1-methylpyrrolidin-3-ylidene]-7²-(Z)-(O-methylxime), monohydrochloride, monohydrate, which corresponds to the following structural formula:



Cefepime hydrochloride is a white to pale yellow powder with a molecular formula of $C_{23}H_{28}ClN_6O_6S_2 \cdot HCl \cdot H_2O$ and a molecular weight of 571.5. It is highly soluble in water. MAXIPIME® (cefepime hydrochloride) for Injection, is supplied for intramuscular or intravenous administration in strengths equivalent to 500 mg, 1 g, and 2 g of cefepime. (See **DOSAGE AND ADMINISTRATION**.) MAXIPIME is a sterile, dry mixture of cefepime hydrochloride and L-arginine. The L-arginine, at an approximate concentration of 725 mg/g of cefepime, is added to control the pH of the constituted solution at 4.0-6.0. Freshly constituted solutions of MAXIPIME will range in color from colorless to amber.

CLINICAL PHARMACOLOGY

Pharmacokinetics

The average plasma concentrations of cefepime observed in healthy adult male volunteers ($n = 9$) at various times following single 30-minute infusions (IV) of cefepime 500 mg, 1 g, and 2 g are summarized in Table 1. Elimination of cefepime is principally via renal excretion with an average (\pm SD) half-life of 2.0 (\pm 0.3) hours and total body clearance of 120.0 (\pm 8.0) mL/min in healthy volunteers. Cefepime pharmacokinetics are linear over the range 250 mg to 2 g. There is no evidence of accumulation in healthy adult male volunteers ($n = 7$) receiving clinically relevant doses for a period of 9 days.

TABLE 3

Tissue or Fluid	Dose/Route	# of Patients	Average Time of Sample Post-Dose (hr)	Average Concentration
Blister Fluid	2 g IV	6	1.5	81.4 μ g/mL
Bronchial Mucosa	2 g IV	20	4.8	24.1 μ g/g
Sputum	2 g IV	5	4.0	7.4 μ g/mL
Urine	500 mg IV	8	0-4	292 μ g/mL
	1 g IV	12	0-4	926 μ g/mL
	2 g IV	12	0-4	3120 μ g/mL

Absorption

The average plasma concentrations of cefepime and its derived pharmacokinetic parameters after intravenous administration are portrayed in Table 1.

TABLE 1

Parameter	500 mg IV	1 g IV	2 g IV
0.5 hr	38.2	78.7	163.1
1.0 hr	21.6	44.5	85.8
2.0 hr	11.6	24.3	44.8
4.0 hr	5.0	10.5	19.2
8.0 hr	1.4	2.4	3.9
12.0 hr	0.2	0.6	1.1
C_{max} , μ g/mL	39.1 (3.5)	81.7 (5.1)	163.9 (25.3)
AUC, hr \cdot μ g/mL	70.8 (6.7)	148.5 (15.1)	284.8 (30.6)
Number of subjects (male)	9	9	9

Following intramuscular (IM) administration, cefepime is completely absorbed. The average plasma concentrations of cefepime at various times following a single IM injection are summarized in Table 2. The pharmacokinetics of cefepime are linear over the range of 500 mg to 2 g IM and do not vary with respect to treatment duration.

TABLE 2

Parameter	500 mg IM	1 g IM	2 g IM
0.5 hr	8.2	14.8	36.1
1.0 hr	12.5	25.9	49.9
2.0 hr	12.0	26.3	51.3
4.0 hr	6.9	16.0	31.5
8.0 hr	1.9	4.5	8.7
12.0 hr	0.7	1.4	2.3
C_{max} , μ g/mL	13.9 (3.4)	29.6 (4.4)	57.5 (9.5)
T_{max} , hr	1.4 (0.9)	1.6 (0.4)	1.5 (0.4)
AUC, hr \cdot μ g/mL	60.0 (8.0)	137.0 (11.0)	262.0 (23.0)
Number of subjects (male)	6	6	12

Distribution

The average steady state volume of distribution is $18.0 (\pm 2.0)$ L. The serum protein-binding of cefepime is approximately 20% and is independent of its concentration in serum.

Cefepime is excreted in human milk. A nursing infant, assuming approximately 1000 mL of human milk, would receive approximately 0.5 mg of cefepime per day. (See **PRECAUTIONS, Nursing Mothers**.)

Concentrations of cefepime achieved in specific body fluids are listed in Table 3.

(See table above)

Data suggest that cefepime does cross the blood-brain barrier. The clinical relevance of these data is uncertain at this time.

Metabolism and Excretion

Cefepime is metabolized to N-methylpyrrolidine (NMP), which is rapidly converted to the N-oxide (NMP-N-oxide). Urinary recovery of unchanged cefepime accounts for approximately 85% of the administered dose. Less than 1% of the administered dose is recovered from urine as NMP-N-oxide, and 2.5% as an epimer of cefepime. Cause renal excretion is a significant pathway of elimination; patients with renal dysfunction and patients requiring hemodialysis require dosage adjustment. (See **DOSAGE AND ADMINISTRATION**.)

Special Populations

Geriatric patients: Cefepime pharmacokinetics have been investigated in elderly (65 years of age and older) ($n = 12$) and women ($n = 12$) whose creatinine clearance was $74.0 (\pm 15.0)$ mL/min. There appeared to be a decrease in cefepime total body clearance as a function of creatinine clearance. Therefore, dosage administration of cefepime in the elderly should be adjusted as appropriate if the creatinine clearance is 60 mL/min or less. (See **DOSAGE AND ADMINISTRATION**.)

Renal Insufficiency: Cefepime pharmacokinetics have been investigated in patients with various degrees of renal insufficiency ($n = 30$). The average half-life in patients requiring hemodialysis was $13.5 (\pm 2.7)$ hours and in patients requiring continuous peritoneal dialysis was $19.0 (\pm 2.0)$ hours. Cefepime total body clearance decreased proportionally with creatinine clearance in patients with abnormal renal function, which serves as the basis for dosage adjustment recommendations in this group of patients. (See **DOSAGE AND ADMINISTRATION**.)

Hepatic Insufficiency: The pharmacokinetics of cefepime were unaltered in patients with impaired hepatic function who received a single 1 g dose ($n = 11$).

Microbiology

Cefepime is a bactericidal agent that acts by inhibiting bacterial cell wall synthesis. Cefepime has a broad spectrum of *in vitro* activity that encompasses a wide range of gram-positive and gram-negative bacteria. Cefepime has a low affinity for chromosomally-encoded beta-lactamase. Cefepime is highly resistant to hydrolysis by most beta-lactamases and exhibits rapid penetration into gram-negative bacterial cells. Within bacterial cells, the molecular targets of cefepime are the penicillin binding proteins. Cefepime has been shown to be active against most of the following microorganisms, both *in vitro* and in clinical infections as described in the **INDICATIONS AND USAGE** section.

Aerobic Gram-Negative Microorganisms:

Enterobacter
Escherichia coli
Klebsiella pneumoniae
Proteus mirabilis
Pseudomonas aeruginosa
Aerobic Gram-Positive Microorganisms:
Staphylococcus aureus (methicillin-susceptible strains only)